AbbVie to launch production of anti-hepatitis drugs in Russia
US pharma company AbbVie (NYSE: ABBV) has started talks with R-Pharm, one of Russia’s largest pharmaceutical producers, for the establishment of a full-cycle of production of anti-hepatitis drugs in Russia at R-Pharm’s plant in the Yaroslavl region, reports The Pharma Letter’s local correspondent.
It is planned that at the initial stage the partners will focus on the manufacture of drugs for the treatment of hepatitis C, with a possibility of a significant expansion of production during the next several years.
According to the press-service of the Yaroslavl region, Alberto Koltsi, vice president of AbbVie, has officially presented a new line of drugs that will be produced in Yaroslavl during the recently closed XIX St Petersburg International Economic Forum.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze